Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference
NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
News
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission…
Accelus Launches TiHawk7™ Titanium-Bonded Multidirectionally Expanding Interbody Cage to Support Endoscopic and MIS Lumbar Fusion Procedures
TiHawk7 combines ultra-low 7mm insertion profile with strong titanium/PEEK adhesion while still allowing for radiographic…
Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline
Scientific Advisory Board of leading experts in oncolytic adenoviruses and gene therapies strengthens transformative clinical…
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., May 05, 2022 (GLOBE NEWSWIRE) —  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage…
Revolo Biotherapeutics to Participate in the LifeSci Partners Immunology & Inflammation Symposium
NEW ORLEANS and LONDON, May 05, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or…
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
SEATTLE, May 05, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
Fulcrum Therapeutics to Participate at the Upcoming BofA Securities 2022 Healthcare Conference
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical…
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting
SANTA ANA, Calif., May 05, 2022 (GLOBE NEWSWIRE) — NKGen Biotech Inc., a biotechnology company…
Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects A…
Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
Up to $100 million of non-dilutive capital from Oxford Finance LLC Extends expected cash runway…
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the…
Ashvattha Therapeutics to Present at UBS Global Healthcare Conference 2022
REDWOOD CITY, Calif., May 05, 2022 (GLOBE NEWSWIRE) — Ashvattha Therapeutics, (“Ashvattha”), a clinical stage…
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights
– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer…
Eyenovia to Report First Quarter 2022 Results on Thursday, May 12
Company to host an investor conference call and webcast at 4:30pm ET on that day…
Vor to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR), a clinical-stage cell…
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics
— Inventions aim to improve bioavailability and reduce drug costs — — Patent applications include…
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight…
Athira Mails Letter to Shareholders Emphasizing the Company’s Strong Position and Qualified Board as it Enters Pivotal Chapter
Urges Shareholders to Vote “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John…
Keros Therapeutics Reports First Quarter 2022 Financial Results
LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”)…